



**Milestone**<sup>™</sup>  
PHARMACEUTICALS

## Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

February 25, 2021

MONTREAL and CHARLOTTE, N.C., Feb. 25, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:

- The Cowen 41<sup>st</sup> Annual Health Care Conference's panel on Cardiovascular Disease and Hospital Products on Thursday, March 4, 2021 at 1:30 p.m. Eastern Time.
- The H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021 on demand beginning at 7:00 a.m. Eastern Time.
- The Oppenheimer 31<sup>st</sup> Annual Healthcare Conference on Tuesday, March 16, 2021 at 10:00 a.m. Eastern Time.

A replay of the pre-recorded H.C. Wainwright presentation and live webcast Oppenheimer presentation can be accessed in the News & Events section of Milestone's website at [www.milestonepharma.com](http://www.milestonepharma.com). An archived replay of the webcasts will be available on the same website for approximately 90 days following the presentations.

### About Milestone Pharmaceuticals

Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit [www.milestonepharma.com](http://www.milestonepharma.com) and follow the Company on Twitter at @MilestonePharma.

### Contact

David Pitts  
Argot Partners  
212-600-1902  
[david@argotpartners.com](mailto:david@argotpartners.com)



**Milestone**<sup>™</sup>  
PHARMACEUTICALS

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-upcoming-investor-conferences-301235125.html>

SOURCE Milestone Pharmaceuticals, Inc.